Drug intelligence / Profile preview

metformin + pantoprazole

Development stage: Unknown
Modality: Small Molecules
Administration: Oral

Overview

A combination of metformin, a biguanide antihyperglycemic agent used for type 2 diabetes mellitus, and pantoprazole, a proton pump inhibitor (PPI) used for acid-related gastrointestinal conditions. This combination may be prescribed when patients with diabetes also have acid-related conditions or experience gastrointestinal side effects from metformin. Studies show that pantoprazole does not impair metformin's effectiveness and may actually improve beta cell function and reduce metformin's gastrointestinal side effects.

Targets

OCT2 (Organic cation transporter 2)AMPK (Adenosine monophosphate–activated protein kinase)ND1 (Mitochondrial electron transport chain complex I)OCT1 (Organic cation transporter 1)OCT3 (Organic cation transporter 3)ATP4A (Potassium–transporting ATPase alpha chain 1)

Beyond the preview

Go deeper on metformin + pantoprazole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on metformin + pantoprazole.

Explore the full profile